Skip to main content
Download PDF

Increasing serum miR-223-3p indicates the onset, severe development, and adverse prognosis of bronchiectasis: a retrospective study

BMC Pulmonary Medicine volume 24, Article number: 354 (2024) Cite this article

Abstract

Background

miR-223-3p has been demonstrated as a Pseudomonas aeruginosa colonization-related miRNA in bronchiectasis (BE), but its clinical value in BE has not been revealed, which is of great significance for the clinical diagnosis and monitoring of BE. This study aimed to identify a reliable biomarker for screening BE and predicting patients’ outcomes.

Methods

The serum expression of miR-223-3p was compared between healthy individuals (n = 101) and BE patients (n = 133) and evaluated its potential in distinguishing BE patients. The severity of BE patients was estimated by BSI and FACED score, and the correlation of miR-223-3p with inflammation and severity of BE patients was evaluated by Pearson correlation analysis. BE patients were followed up for 3 years, and the predictive value of miR-223-3p in prognosis was assessed by logistic regression analysis.

Results

Significant upregulation of miR-223-3p was observed in BE patients, which significantly distinguished BE patients and showed positive correlations with C-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR) of BE patients. Additionally, miR-223-3p was also positively correlated with BSI and FACED scores, indicating its correlation with inflammation and severity of BE. BE patients with adverse prognoses showed a higher serum miR-223-3p level, which was identified as an adverse prognostic factor and discriminated patients with different prognoses.

Conclusion

Increasing serum miR-223-3p can be considered a biomarker for the onset, severity, and prognosis of BE.

Peer Review reports

Background

Bronchiectasis (BE) is a kind of pathological injury in the trachea and bronchial tissues. The basic clinical symptoms are recurrent cough, phlegm, and even hemoptysis [1]. Dilatations of the airways is the main feature of BE, which is pathological injury and is irreversible, continuous, and permanent with a long-term course of disease, which has a serious influence on patients’ daily lives [2]. The onset of BE involves various factors, including the chronic colonization of bacteria and airway inflammation [3]. The clinical diagnosis of BE is mainly based on radiological examinations, and the severity was also defined based on the radiological findings. However, due to the complex disease conditions and the similar symptoms with other trachea and bronchial diseases, the radiological diagnosis of BE is always incomplete and lacks prediction of disease development and outcomes [4]. On the other hand, the employment of radiological examination is limited to patients’ conditions and is not suitable for all patients. The early detection of BE is of great clinical importance, and exploring easily detected and reliable biomarkers for BE would help predict patients’ prognosis and provide a reference for the early intervention and adjustment of therapeutic efficiency, which has become a research hot point and challenging problem in the clinic [5].

microRNAs (miRNAs) are a series of small non-coding RNAs produced by the processing of single-stranded RNA precursor by the Dicer enzymes, which have been demonstrated to play vital roles in various life activities. Several studies have also reported the functional role of miRNAs in the occurrence of BE and revealed their regulatory mechanisms underlying disease progression. Pseudomonas aeruginosa is one of the most important pathogenic bacteria, of which the colonization would induce severe development and result in adverse prognosis of patients [6, 7]. A previous study identified several miRNA candidates correlated with P. aeruginosa colonization in the sputum of BE, where miR-223-3p was included [8]. miR-223-3p has been suggested to mediate the disease course of various respiratory diseases, including asthma, acute respiratory distress, chronic obstructive pulmonary disease, and COVID-19-induced pneumonia [9,10,11,12]. Additionally, miR-223-3p was also revealed to regulate inflammation in human diseases, which seriously affected the severity of BE [13,14,15]. Therefore, according to previous evidence, miR-223-3p was hypothesized of great potential to diagnose BE and predict patients’ outcomes, which lacks confirming data.

This study enrolled a group of BE patients with healthy individuals as the control group. Through comparing serum miR-223-3p levels and summarizing the severity and prognosis data of BE patients, the significance of miR-223-3p in discriminating BE and predicting patients’ prognosis was disclosed, aiming to identify a novel biomarker for BE.

Methods

Enrollment of study subjects

A total of 133 BE patients were enrolled from The First Dongguan Affiliated Hospital of Guangdong Medical University from January 2018 to December 2020. The diagnosis of BE was based on criteria for adults with the help of high-resolution computed tomography (HRCT) examinations [16], combined with the following clinical symptoms: (1) cough, sputum, and dyspnea; (2) chest pain, different degrees of hemoptysis, loss of appetite, fever, anemia, weight loss, and fatigue; (3) lung moist rales can be heard, and some patients were with thick dry rales or clubbing toes. The signs for diagnosing BE by HRCT included direct signs and indirect signs. The direct signs were: (1) the inner diameter of bronchus/accompanying pulmonary artery over 1 cm; (2) the bronchus did not taper from the center to the periphery; (3) a bronchial shadow observed 1 cm from the peripheral pleural or close to the mediastinal pleura. The indirect signs were: (1) thickening bronchial wall; (2) mucous impaction; (3) “mosaic” sign or “gas trapping” observed by expiratory CT; (4) columnar or sac-like changes, tracheowall thichening (the bronchial inner diameter < 80% of outer diameter) and tree bud signs. Enrolled patients should be clearly aware and cooperative and had never received treatments of anti-infection, bronchodilator, or leukotriene inhibitors within 3 months prior to the study. Patients combined with malignant tumors, lung diseases, immune deficiency, or severe hemoptysis in the lungs were excluded.

Another 101 healthy individuals were enrolled in the physical examination center of our hospital during the same period. All participants had signed informed consent, and the study had obtained approval from the Ethics Committee of The First Dongguan Affiliated Hospital of Guangdong Medical University. BE patients were followed up for 3 years to summarize the outcomes of patients. Adverse complications, such as pulmonary heart disease, respiratory failure, and emphysema, and deaths were defined as adverse outcomes.

Sample collection and preparation

Fasting elbow venous blood was collected from all study subjects. A part of the blood samples was centrifugated at 4000 g for 15 min to isolate serum, and another part was stored in an anti-coagulation tube used for the analysis of inflammation indicators, including, C-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR).

Analyses of inflammation indicators

The levels of CRP (C-Reactive protein ELISA Kit, ab260058, Abcam, USA), PCT (Procalcitonin ELISA Kit, ab221828, Abcam, USA), and IL-6 (IL-6 ELISA Kit, ab178013, Abcam, USA) were analyzed by enzyme-linked immunosorbent assay performed on whole blood samples with corresponding kits according to the manufacturers’ instructions.

NLR was calculated based on the counts of neutrophil and lymphocyte measured by a Sysmex XN-10 Automated Hematology Analyzer (Sysmex GmbH, Germany).Evaluation of BE severity.

The severity of BE was evaluated by the bronchiectasis severity index (BSI) and FACED scores according to previous studies [17,18,19]. BSI score summarized the features of patients, including age, BMI, the time of acute exacerbations within 1 year, the time of hospitalization within 2 years, the percentage forced expiratory volume in one second (FEV1) of the estimated value, the number of lobe segments involved in imaging, modified medical research council dyspnea scale, the colonization of P. aeruginosa and other bacteria. The total score is 26 points, where 0–4 points indicate mild BE, 5–8 points indicate moderate BE, and over 9 points indicate severe BE.

The FACED score included similar features with a total score of 7 points, where 0–2 points indicate mild BE, 3–4 points indicate moderate BE, and 5–7 points indicate severe BE.

Real-time quantitative PCR

Total RNA was extracted from serum using QIAzol Lysis Reagent (QIAGEN, Germany) and evaluated by the ratio of OD260/280 (ranging from 1.8 to 2.2). Reversed transcription was conducted with a Reverse Transcription kit (QIAGEN, Germany) to generate cDNA. Then, amplification was performed on the ABI 7900 PCR system (Applied Biosystem, USA) with SYBR Green. The relative expression of miR-223-3p was calculated with the 2−ΔΔCT method with cel-miR-39 as the internal reference.

Statistical analyses

All data have been confirmed in accordance with the normal distribution by a P-P plot using SPSS 23.0 software. A difference comparison between the two groups was performed with a student’s t-test (P < 0.05). The receiver operating curve (ROC) was performed to evaluate the significance of miR-223-3p in distinguishing BE patients and discriminating patients with different prognoses, and the risk factors for adverse prognosis of BE patients were identified by logistic regression analysis. The diagnostic cutoff, sensitivity, and specificity of miR-223-3p was obtained at the maximum Yuden index of ROC. The correlation of miR-223-3p with inflammation and severity of BE patients was assessed by Pearson correlation analysis.

Results

Upregulated miR-223-3p distinguished BE patients from healthy individuals and indicated disease severity

Healthy individuals included 66 males and 35 females with an average age of 59.59 ± 7.77 years, while BE patients were composed of 88 male patients and 45 female patients with an average age of 59.80 ± 9.06 years. The age and gender composition are not statistically different (data not shown). Significant upregulation of miR-223-3p was observed in BE patients relative to healthy individuals (Fig. 1a), which discriminated BE patients with a relatively high sensitivity (92.84%) and specificity (81.19%) indicating by ROC with the cutoff of 1.105 (AUC = 0.916, Fig. 1b).

Fig. 1
figure 1

Expression and diagnostic value of miR-223-3p in BE. (a) serum expression. (b) ROC curve. ****P < 0.0001

Full size image

The inflammation of BE patients was evaluated by the levels of CRP, PCT, IL-6, and NLR. Significantly positive correlations of miR-233-3p with these indicators were observed with the correlation coefficients of rCRP = 0.902 (Fig. 2a), rPCT = 0.807 (Fig. 2b), rIL−6 = 0.882 (Fig. 2c), and rNLR = 0.851 (Fig. 2d). While positive correlations were also revealed in the severity of BE with the serum miR-223-3p levels. miR-223-3p showed positive correlation with the BSI score (r = 0.798, Fig. 2e) and FACED score (r = 0.814, Fig. 2f).

Fig. 2
figure 2

Correlation of miR-223-3p with inflammation and severity. a-d. correlation with inflammation indicators, CRP (a), PCT (b), IL-6 (c), NLR (d). e-f. correlation with severity indicators, BSI score (e), and FACED score (f)

Full size image

Increased serum miR-223-3p levels predicted the adverse prognosis of BE patients

According to the 3-year follow-up data, patients were divided into a good-prognosis group and an adverse-prognosis prognosis group. Patients with adverse prognoses showed a higher PCT level (P = 0.021), BSI score (P = 0.008), and FACED score (P = 0.012) than that of patients with good prognoses. CRP, IL-6, and NLR showed no significant difference between the two groups (Table 1). The serum miR-223-3p was relatively higher in patients with adverse prognoses than patients with good prognoses (Fig. 3a). Serum miR-223-3p also showed significant diagnostic value in discriminating patients with adverse prognoses with the cutoff of 1.255 (Fig. 3b). Logistic regression analysis demonstrated that miR-223-3p was the most significant risk factor for the adverse prognosis of BE patients (OR = 16.224, P < 0.0001), as well as BSI score (OR = 2.919, P = 0.28), FACED score (OR = 2.751, P = 0.035), PCT (OR = 2.395, P = 0.048), and NLR (OR = 2.551, P = 0.049, Table 2).

Table 1 Baseline information of BE patients with different outcomes
Full size table
Fig. 3
figure 3

Expression and correlation of miR-223-3p with prognosis of BE patients. (a) serum expression. (b) ROC curve. ****P < 0.0001

Full size image
Table 2 Logistic regression analysis evaluating risk factor for adverse prognosis in BE patients
Full size table

Discussion

Significance of miR-223-3p in diagnosing BE patients

Exploring accurate, convenient, efficient, and non-invasive diagnostic biomarkers for BE has always been an urgent problem to solve in the clinic. miR-223-3p is a key regulator in respiratory diseases that screens onset, predicts patients’ survival, regulates disease development, and modulates inflammation [20,21,22,23,24]. Blood analysis is a common non-invasive examination for primarily screening human diseases. Here, increasing serum miR-223-3p level was observed in BE patients and showed significant value in distinguishing BE patients. The obtained diagnostic cutoff for miR-223-3p in BE was 1.105. It means patients with a serum miR-223-3p over 1.105 are considered of high property of BE. However, there were some healthy individuals showed higher serum miR-223-3p over the cutoff in the study subjects of the present study. The AUC value of ROC (0.916) indicates the diagnostic efficiency, therefore, serum miR-223-3p cannot totally diagnose BE patients. Additionally, the relatively small sample size is not large enough to confirm miR-223-3p as a diagnostic index including in clinical practice, the observed increasing level of miR-223-3p might assist in improving the accuracy and specificity of screening BE, which can be verified in the clinic.

Correlation of miR-223-3p with inflammation in BE patients

Inflammation indicators have been considered effective means to screen infectious diseases and evaluate the disease conditions [25]. CRP, PCT, IL-6, and NLR are sensitive inflammation indicators. According to clinical experiences, CRP, PCT, and IL-6 showed rapid increase in the early stage of infection [26, 27]. The increase of PCT is earlier and is specific to bacterial infection, fungal infection, sepsis, and multiple organ failure [28, 29]. The sensitivity of IL-6 is higher than CRP and PCT [30]. NLR directly represents the balance between neutrophils, lymphocytes, and inflammatory activators and could further indicate infection or acute inflammation. Moreover, NLR has been demonstrated as a biomarker for BE [31]. There have been studies that combined these inflammation indicators and found combining could improve the diagnosis of pulmonary infection and help predict disease severity. A previous study demonstrated increasing miR-223-3p in leukocytes was positively correlated with IL-17, which is critically involved in inflammation and mediates immune response [9]. The inflammatory indicators were positively correlated with the serum miR-223-3p levels in BE patients, suggesting its ability to assess the degree of inflammation and potential to predict disease severity.

Correlation of miR-223-3p with the severity of BE patients

The study employed two assessing scales for the severity of BE patients. Although the features and indicators are similar between the BSI score and the FACED score, the clinical significance of the two scores is slightly different [32]. BSI score shows more potential in predicting deterioration, hospitalization, health status, and death, while FACED score emphasizes predicting future acute exacerbations and risk of hospitalization [33]. Therefore, BSI showed a higher significance in predicting the adverse prognosis of BE patients than the FACED score in the present study. A positive correlation of miR-223-3p was observed with both two scores, indicating miR-223-3p is of great significance in predicting severe development and adverse outcomes of BE patients, which was further validated based on the follow-up data. However, this study only focused on the correlation of miR-223-3p with patients’ disease severity, overlooking the changes in miR-223-3p when the severity progressed. Therefore, there is a need for a dynamic study on the expression of miR-223-3p during the progression of BE, which would provide more reference for the clinical application of miR-223-3p in monitoring BE.

Correlation of miR-223-3p with the prognosis of BE patients

With the 3-year follow-up survey, over half of BE patients experienced adverse outcomes, including pulmonary heart disease, respiratory failure, emphysema, and even death. Pulmonary heart disease is one of the most common complications of BE, due to lung hyperinflation, increased hypoxemia, and systemic inflammation during the onset of BE. The pathological injuries in the trachea and bronchial tissues dramatically influenced the work of the respiratory system, and therefore, respiratory diseases are also frequent complications in BE [34]. Although this study had not differentiated different complications in patients with adverse prognoses, the significance of miR-223-3p was demonstrated. The serum miR-223-3p levels were higher in patients with adverse prognosis and were identified as a risk factor for adverse prognosis. As expected, the increasing serum miR-223-3p level discriminated patients with good prognosis and adverse prognosis sensitively and specifically. Therefore, besides predicting severe disease development, serum miR-223-3p could also be considered an indicator of the unfavorable outcomes of BE. The significance of miR-223-3p in specific complications needs further investigations to completely reveal the prognostic value in BE.

Serum miR-223-3p showed great significance in screening and prognosis prediction of BE, and it can be considered an auxiliary indicator for suspected patients or patients not available for radiological examination. Compared with protein analyses, the quantification of serum miR-223-3p by PCR is quicker and more convenient, but the diagnostic cutoff needs further larger-sample-size investigations.

Conclusions

In conclusion, the upregulation of serum miR-223-3p could indicate the onset of BE, severe disease development, and adverse prognosis, suggesting the potential of serum miR-223-3p in diagnosing and prognosis predicting of BE.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

BE:

Bronchiectasis

BSI:

Bronchiectasis severity index

CRP:

C-reactive protein

FEV1:

Forced expiratory volume in one second

HRCT:

High-resolution computed tomography

IL-6:

Interleukin 6

miRNAs:

MicroRNAs

NLR:

Neutrophil-to-lymphocyte ratio

PCT:

Procalcitonin

ROC:

Receiver operating curve

References

  1. Magis-Escurra C, Reijers MH. Bronchiectasis. BMJ clinical evidence. 2015;2015.

  2. O’Donnell AE. Bronchiectasis - a clinical review. N Engl J Med. 2022;387(6):533–45. https://doi.org/10.1056/NEJMra2202819

    Article  PubMed  Google Scholar 

  3. O’Neill K, O’Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis. Respirol (Carlton Vic). 2019;24(3):227–37. https://doi.org/10.1111/resp.13459

    Article  Google Scholar 

  4. Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respiratory Med. 2018;6(9):715–26. https://doi.org/10.1016/s2213-2600(18)30053-5

    Article  CAS  Google Scholar 

  5. Visser SK, Bye P, Morgan L. Management of bronchiectasis in adults. Med J Australia. 2018;209(4):177–83. https://doi.org/10.5694/mja17.01195

    Article  PubMed  Google Scholar 

  6. Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649–62. https://doi.org/10.1080/17476348.2021.1906225

    Article  CAS  PubMed  Google Scholar 

  7. Chai YH, Xu JF. How does pseudomonas aeruginosa affect the progression of bronchiectasis? Clin Microbiol Infect. 2020;26(3):313–8. https://doi.org/10.1016/j.cmi.2019.07.010

    Article  CAS  PubMed  Google Scholar 

  8. Huang Y, Chen CL, Yuan JJ, Li HM, Han XR, Chen RC, et al. Sputum exosomal microRNAs profiling reveals critical pathways modulated by pseudomonas aeruginosa colonization in bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2019;14:2563–73. https://doi.org/10.2147/COPD.S219821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Xu W, Wang Y, Wang C, Ma Y, He S, Kang Y, et al. Increased miR-223-3p in leukocytes positively correlated with IL-17A in plasma of asthmatic patients. Iran J Allergy Asthma Immunol. 2020;19(3):289–96. https://doi.org/10.18502/ijaai.v19i3.3456

    Article  CAS  PubMed  Google Scholar 

  10. Curcio R, Poli G, Fabi C, Sugoni C, Pasticci MB, Ferranti R, et al. Exosomal miR-17-5p, miR-146a-3p, and mir-223-3p correlate with radiologic sequelae in survivors of COVID-19-related acute respiratory distress syndrome. Int J Mol Sci. 2023;24(17). https://doi.org/10.3390/ijms241713037

  11. Roffel MP, Maes T, Brandsma CA, van den Berge M, Vanaudenaerde BM, Joos GF, et al. MiR-223 is increased in lungs of patients with COPD and modulates cigarette smoke-induced pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol. 2021;321(6):L1091–104. https://doi.org/10.1152/ajplung.00252.2021

    Article  CAS  PubMed  Google Scholar 

  12. Morales L, Oliveros JC, Enjuanes L, Sola I. Contribution of host miRNA-223-3p to SARS-CoV-induced lung inflammatory pathology. mBio. 2022;13(2):e0313521. https://doi.org/10.1128/mbio.03135-21

    Article  PubMed  Google Scholar 

  13. Qi X, Wang R, Jin L, Tian Y, Jin H, Han Y et al. MiR-223-3p aggravates ocular inflammation in Sjögren’s syndrome. Endocrine, metabolic & immune disorders drug targets. 2023;23(8):1087–95. https://doi.org/10.2174/1871530323666230103123831

  14. Tang H, Lin Y, Huang L, Hu J. MiR-223-3p regulates autophagy and inflammation by targeting ATG16L1 in fusarium solani-induced keratitis. Investig Ophthalmol Vis Sci. 2022;63(1):41. https://doi.org/10.1167/iovs.63.1.41

    Article  CAS  Google Scholar 

  15. Tian J, Zhou D, Xiang L, Liu X, Zhang H, Wang B, et al. MiR-223-3p inhibits inflammation and pyroptosis in monosodium urate-induced rats and fibroblast-like synoviocytes by targeting NLRP3. Clin Exp Immunol. 2021;204(3):396–410. https://doi.org/10.1111/cei.13587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Writing BEC, Pulmonary Infection Assembly G. Expert consensus on the diagnosis and treatment of adult bronchiectasis in China. Zhonghua Jie He He Hu Xi Za Zhi. 2021;44(4):311–21. https://doi.org/10.3760/cma.j.cn112147-20200617-00717

    Article  Google Scholar 

  17. Ju S, Jeong JH, Heo M, Heo IR, Kim TH, Kim HC, et al. Serum albumin is a predictor of respiratory hospitalization in patients with bronchiectasis. Chron Respir Dis. 2021;18:14799731211017548. https://doi.org/10.1177/14799731211017548

    Article  PubMed  PubMed Central  Google Scholar 

  18. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85. https://doi.org/10.1164/rccm.201309-1575OC

    Article  PubMed  PubMed Central  Google Scholar 

  19. Martinez-Garcia MA, de Gracia J, Vendrell Relat M, Giron RM, Maiz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357–67. https://doi.org/10.1183/09031936.00026313

    Article  PubMed  Google Scholar 

  20. Li G, Zong X, Cheng Y, Xu J, Deng J, Huang Y, et al. Mir-223-3p contributes to suppressing NLRP3 inflammasome activation in Streptococcus equi ssp. zooepidemicus infection. Vet Microbiol. 2022;269:109430. https://doi.org/10.1016/j.vetmic.2022.109430

    Article  CAS  PubMed  Google Scholar 

  21. Pinho JD, Silva GEB, Teixeira Júnior AAL, Belfort MRC, Mendes JM, Cunha IWD, et al. MIR-107, MIR-223-3P and MIR-21-5P reveals potential biomarkers in penile cancer. Asian Pac J cancer Prevention: APJCP. 2020;21(2):391–7. https://doi.org/10.31557/apjcp.2020.21.2.391

    Article  CAS  Google Scholar 

  22. Tang P, Xu Y, Zhang J, Nan J, Zhong R, Luo J, et al. Mir-223-3p mediates the diabetic kidney disease progression by targeting IL6ST/STAT3 pathway. Biochem Biophys Res Commun. 2023;648:50–8. https://doi.org/10.1016/j.bbrc.2023.01.045

    Article  CAS  PubMed  Google Scholar 

  23. You D, Qiao Q, Ono K, Wei M, Tan W, Wang C, et al. Mir-223-3p inhibits the progression of atherosclerosis via down-regulating the activation of MEK1/ERK1/2 in macrophages. Aging. 2022;14(4):1865–78. https://doi.org/10.18632/aging.203908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wu X, Zhang X, Li D, Zhu Z. Plasma level of miR-99b may serve as potential diagnostic and short-term prognostic markers in patients with acute cerebral infarction. J Clin Lab Anal. 2020;34(3):e23093. https://doi.org/10.1002/jcla.23093

    Article  PubMed  PubMed Central  Google Scholar 

  25. Keir HR, Chalmers JD. Bronchiectasis enters the inflammation era. Respirol (Carlton Vic). 2022;27(7):488–9. https://doi.org/10.1111/resp.14263

    Article  Google Scholar 

  26. An X, Zhang X, ShangGuan Y. Application of PCT, IL-6, CRP, and WBC for diagnosing neonatal sepsis. Clin Lab. 2023;69(8). https://doi.org/10.7754/Clin.Lab.2022.220737

  27. Plesko M, Suvada J, Makohusova M, Waczulikova I, Behulova D, Vasilenkova A, et al. The role of CRP, PCT, IL-6 and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients. Neoplasma. 2016;63(5):752–60. https://doi.org/10.4149/neo_2016_512

    Article  CAS  PubMed  Google Scholar 

  28. Li Y, Min L, Zhang X. Usefulness of procalcitonin (PCT), C-reactive protein (CRP), and white blood cell (WBC) levels in the differential diagnosis of acute bacterial, viral, and mycoplasmal respiratory tract infections in children. BMC Pulm Med. 2021;21(1):386. https://doi.org/10.1186/s12890-021-01756-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2004;39(2):206–17. https://doi.org/10.1086/421997

    Article  CAS  Google Scholar 

  30. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143–59. https://doi.org/10.1042/CS20110340

    Article  CAS  PubMed  Google Scholar 

  31. Georgakopoulou VE, Trakas N, Damaskos C, Garmpis N, Karakou E, Chatzikyriakou R, et al. Neutrophils to lymphocyte ratio as a biomarker in bronchiectasis exacerbation: a retrospective study. Cureus. 2020;12(8):e9728. https://doi.org/10.7759/cureus.9728

    Article  PubMed  PubMed Central  Google Scholar 

  32. Costa JC, Machado JN, Ferreira C, Gama J, Rodrigues C. The bronchiectasis severity index and FACED score for assessment of the severity of bronchiectasis. Pulmonology. 2018. https://doi.org/10.1016/j.rppnen.2017.08.009

    Article  PubMed  Google Scholar 

  33. Rosales-Mayor E, Polverino E, Raguer L, Alcaraz V, Gabarrus A, Ranzani O, et al. Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. PLoS ONE. 2017;12(4):e0175171. https://doi.org/10.1371/journal.pone.0175171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Choi H, Chalmers JD. Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. Ann Transl Med. 2023;11(1):25. https://doi.org/10.21037/atm-22-3437

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not Applicable.

Funding

This study was funded by Dongguan Social Development Science and Technology Program (No. 20211800904362) and Natural Science Foundation of Guangdong Province Basic and Applied Basic Research Fund Upper-level Project (No. 2023A1515012380).

Author information

Authors and Affiliations

  1. Respiratory Medicine Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, No. 42, Jiaoping Road, Tangxia Town, Dongguan, 523710, China

    Jia Fang, Chenghui Lin, Wangli Qiu & Yun Wang

  2. Medical Laboratory Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, 523710, China

    Yao Xu

  3. Department of Emergency, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, 523710, China

    Jiewen Yang

  4. Department of Gastroenterology, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, 523710, China

    Dongxu Zhai

  5. Department of Clinical Pharmacy, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, 523710, China

    Qingyuan Zhuang

  6. Department of Ultrasonography, The First Dongguan Affiliated Hospital of Guangdong Medical University, No. 42, Jiaoping Road, Tangxia Town, Dongguan, 523710, China

    Longjuan Zhang

Authors
  1. Jia Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chenghui Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiewen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dongxu Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingyuan Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wangli Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Longjuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y W and LJ Z designed the research study. Y X, CH L, JW Y, DX Z and QY Z performed the research. J F and WL Q analyzed the data. J F, Y W and LJ Z wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yun Wang or Longjuan Zhang.

Ethics declarations

Ethics approval and consent to participate

The study had obtained approval from the Ethics Committee of The First Dongguan Affiliated Hospital of Guangdong Medical University.

Consent for publication

All participants had signed informed consent.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fang, J., Xu, Y., Lin, C. et al. Increasing serum miR-223-3p indicates the onset, severe development, and adverse prognosis of bronchiectasis: a retrospective study. BMC Pulm Med 24, 354 (2024). https://doi.org/10.1186/s12890-024-03170-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-024-03170-y

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us